Search Results
150 items found for "Confo Therapeutics"
- LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell migration
Moreover, our findings propose a therapeutic potential in combined CXCR4 and LPA1 inhibitors for cancer
- 24-02 Dr GPCR Newsletter
symposiums: June 07th - Structural and Molecular Insights in GPCR Function October 11th - GPCRs as Therapeutic
- 24-04 Dr GPCR Newsletter
your calendar: June 07th - Structural and Molecular Insights in GPCR Function October 11th - GPCRs as Therapeutic
- GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment
These findings provide a promising therapeutic approach to selectively induce ferroptosis in glioblastoma
- 24-01 Dr GPCR Newsletter
Michel Bouvier June 07th - S tructural and Molecular Insights in GPCR Function October 11th - GPCRs as Therapeutic
- 24-03 Dr GPCR Newsletter
next symposia: June 07th - Structural and Molecular Insights in GPCR Function October 11th - GPCRs as Therapeutic
- 21-04 Dr GPCR Newsletter
Transition (EMT) Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: Implications for therapeutic Meetings & Talks GPCR Colloquium May 10-11,2021 Psychedelic Therapeutics and Drug Development Conference
- GPCR Retreat Schedule 2023
San Diego Read More Friday, November 3rd / 3:55 PM Inhibition of Relaxin Autocrine Signaling Confers Therapeutic
- 21-06 Dr GPCR Newsletter
receives an Established Investigator Academic-Industry Partnership Award Interview With CEO Of Blue Therapeutics
- 21-02 Dr GPCR Newsletter
associated to MRGPRX2-mediated mast cell degranulation and cell activation modules, defining a new therapeutic